VARIVAX™ 2007 process
Sponsors
Merck Sharp & Dohme LLC
Conditions
Varicella
Phase 3
A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)
WithdrawnNCT01626794
Start: 2014-07-31End: 2015-10-31Updated: 2015-01-27
Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)
CompletedNCT02062502
Start: 2014-03-07End: 2015-10-13Updated: 2018-10-30